Quantcast

Latest tumor Stories

2014-08-21 12:29:29

The Jeffrey Epstein VI Foundation funds a study showing tumor growth. NEW YORK, Aug. 21, 2014 /PRNewswire/ -- Mathematic studies at the Program for Evolutionary Dynamics (PED) at Harvard University, and funded by the Jeffrey Epstein VI Foundation, have shown that the most aggressive cells within tumors can be visually identified for elimination. These aggressive cells are the driver mutations that drive the tumor's growth. The study, which shows a topological map of what to look for...

2014-08-19 08:29:50

VAL-083 Phase I/II VAL-083 clinical trial advances to 50mg/m(2) cohort VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 19, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today a protocol amendment to allow for expanded dosing in its VAL-083 clinical trial had been filed with the U.S. Food and Drug Administration (FDA) and that a new cohort of a new 50mg/m(2) has been opened at three clinical trial sites in the United...

Cancer cell containing nanoparticles
2014-08-14 03:00:53

University of Cambridge A smart technology which involves smuggling gold nanoparticle into brain cancer cells has proven highly effective in lab-based tests A "Trojan horse" treatment for an aggressive form of brain cancer, which involves using tiny nanoparticles of gold to kill tumor cells, has been successfully tested by scientists. The ground-breaking technique could eventually be used to treat glioblastoma multiforme, which is the most common and aggressive brain tumor in adults,...

2014-08-12 08:29:40

IRVING, Texas, Aug. 12, 2014 /PRNewswire/ -- Doctors at the LSU Health Shreveport Feist-Weiller Cancer Center will now have access to innovative, precision-medicine technology that determines the unique biological characteristics of each individual patient's cancer tumor. Once that information is known, physicians can identify tailored chemotherapy or radiation regimens to attack it. The new capability is the result of emerging technology called tumor profiling. Feist-Weiller will...

2014-08-11 08:29:09

Patented Technology Enables Accurate Delivery of a Chemotherapeutic Drug to Targeted Tumor Cells, Reducing Drug-related Toxicity without Sacrificing Therapeutic Impact SYDNEY, Aug. 11, 2014 /PRNewswire/ -- EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No....

2014-08-08 11:22:18

OSA A new hand-held device that uses lasers and sound waves may change the way doctors treat and diagnose melanoma, according to a team of researchers from Washington University in St. Louis. The instrument, described in a paper published today in The Optical Society’s (OSA) journal Optics Letters, is the first that can be used directly on a patient and accurately measure how deep a melanoma tumor extends into the skin, providing valuable information for treatment, diagnosis or...

2014-08-08 11:20:47

Cell Transplantation Center of Excellence for Aging and Brain Repair Induced immunorejection may eliminate tumors post-cell transplantation Recent studies have shown that transplanting induced pluripotent stem cell-derived neural stem cells (iPS-NSCs) can promote functional recovery after spinal cord injury in rodents and non-human primates. However, a serious drawback to the transplantation of iPS-NSCs is the potential for tumor growth, or tumorogenesis, post-transplantation. In an...

2014-08-05 08:33:58

POINT ROBERTS, Wash. and NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Investorideas.com, a global news source covering leading sectors including biotech, issues an exclusive Q&A interview with Dr. Craig Dionne, PhD, GenSpera's (OTCQB: GNSZ) CEO. Dr. Dionne discusses the company's lead drug G-202 and how they have taken a powerful toxin named thapsigargin to selectively target and kill cancer cells. He also shares insight into the key points that make them different from competitive...

2014-08-05 08:33:13

Peer-Reviewed Case Study from Fox Chase Cancer Center Demonstrates Value of Company's Unique Approach to Precision Medicine to Uncover Critical Treatment Insights IRVING, Texas, Aug. 5, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today publication of a case study in which the company's comprehensive tumor profiling service, Caris Molecular Intelligence(TM), helped guide successful...

2014-08-04 09:40:28

University of California - San Diego Biomarker for head and neck cancers identified Although mutations in a gene dubbed "the guardian of the genome" are widely recognized as being associated with more aggressive forms of cancer, researchers at the University of California, San Diego School of Medicine have found evidence suggesting that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities, at least in squamous cell head and neck...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related